Therapeutic Asset Ratings
143 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Tas-102
Colon Adenocarcinoma
University of California, Irvine
P1
CC
(43)
Spedox-6
Cervical Cancer
University of California, Irvine
P1/2
CC
(41)
Spedox-6
Triple-Negative Breast Carcinoma
University of California, Irvine
P1/2
CC
(41)
Spedox-6
Non-Small Cell Lung Carcinoma
University of California, Irvine
P1/2
CC
(40)
Spedox-6
Ovarian Cancer
University of California, Irvine
P1/2
CC
(40)
Trifluridine/Tipiracil Hydrochloride Combination Agent Tas-102
Advanced Solid Tumors
Regeneron Pharmaceuticals
P1/2
CC
(40)
Actinium Ac 225-Dota-Daratumumab
Myelodysplastic Syndrome
City of Hope Medical Center
P1
C
(39)
Tas-102
Biliary Tract Cancer
Taiho Pharmaceutical Co., Ltd.
P1
C
(39)
Tas-102
Head And Neck Cancer
Taiho Pharmaceutical Co., Ltd.
P1
C
(39)
Actinium Ac 225-Dota-Daratumumab
Acute Lymphoblastic Leukemia
City of Hope Medical Center
P1
C
(37)
Tas-102
Esophageal Cancer
Taiho Pharmaceutical Co., Ltd.
P1
C
(37)
Tas-102
Gastric Cancer
Taiho Pharmaceutical Co., Ltd.
P1
C
(37)
Tas-102
Pancreatic Ductal Adenocarcinoma
Taiho Pharmaceutical Co., Ltd.
P1
C
(37)
Actinium Ac 225-Dota-Daratumumab
Acute Myeloid Leukemia
City of Hope Medical Center
P1
C
(36)
Tas-102
Non-Small Cell Lung Carcinoma
Taiho Pharmaceutical Co., Ltd.
P1
C
(36)
Tas-102
Fruquintinib
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
D
(30)
Trifluridine/Tipiracil Hydrochloride Combination Agent Tas-102
Colorectal Cancer
Bayer
D
(30)
Ddgp
Extranodal Nasal NK/T Cell Lymphoma
Ruijin Hospital
P3
NR
(0)
Showing 126 to 143 of 143 assets
Previous
Page 6 of 6
Next
